Detalhe da pesquisa
1.
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
Circulation
; 147(16): 1192-1203, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779348
2.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Lancet
; 390(10106): 1962-1971, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28859947
3.
The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience.
Arch Med Sci
; 18(4): 1095-1099, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35982912
4.
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
JAMA Cardiol
; 4(7): 613-619, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31116355